Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
• Prof Fabien Zoulim will report that the Phase 1b trial reached its safety primary endpoint and that the therapeutic vaccine TG1050 breaks immune tolerance in patients with chronic hepatis B virus (HBV) infection
• Transgene will also present new and promising preclinical data set on combination studies of TG1050 with antivirals and immunomodulators
Strasbourg, France – October 10, 2018, 6:00 pm CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announces that the detailed results of the Phase 1b clinical trial using TG1050 confirm that the safety primary endpoint was reached and that TG1050 breaks immune tolerance through improvement of immune response directed against HBV antigens in patients with chronic HBV receiving standard antiviral therapies. The complete Phase 1b data will be presented by Prof Fabien Zoulim, MD, PhD, on November 9, 2018, at the annual meeting of the AASLD (American Association for the Study of Liver Diseases) in San Francisco (USA).
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer